Sun Pharma Inks $55.5 Million Deal with Samsung BioLogics for Anti-Psoriasis drug


Sun Pharma and Samsung BioLogics today reported a strategic long-term manufacturing agreement for Tildrakizumab utilized for treatment of psoriasis.

“The agreement was gone into by Sun Pharma’s entirely owned subsidiary and Samsung BioLogics…Sun Pharma has appointed Samsung BioLogics to manufacture Tildrakizumab, an investigational IL-23p19 inhibitor being evaluated for the treatment of moderate to severe plaque psoriasis,” the organization said in a BSE filing.

Sun Pharma said the approximate value of the contract will be USD 55.5 million, other financial details of the agreement are confidential.

It additionally stated: “Filings for this novel investigational biologic has been accepted for review by the US Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017)”.

The agreement was signed at Samsung BioLogics’ headquarter in Incheon, South Korea.

Shares of Sun Pharma were trading 0.55% bring down at Rs. 548.45 on BSE.